自身免疫性肝炎

Manns MP, Czaja AJ, Gorham JD, et al. Diagnosis and management of autoimmune hepatitis. Hepatology. 2010;51:2193-2213.全文  摘要

Gleeson D, Heneghan MA; British Society of Gastroenterology. British Society of Gastroenterology (BSG) guidelines for management of autoimmune hepatitis. Gut. 2011 Dec;60(12):1611-29.全文  摘要

Strassburg CP, Manns MP. Treatment of autoimmune hepatitis. Semin Liver Dis. 2009 Aug;29(3):273-85. 摘要

Selvarajah V, Montano-Loza AJ, Czaja AJ. Systematic review: managing suboptimal treatment responses in autoimmune hepatitis with conventional and nonstandard drugs. Aliment Pharmacol Ther. 2012 Oct;36(8):691-707.全文  摘要

1. Manns MP, Czaja AJ, Gorham JD, et al. Diagnosis and management of autoimmune hepatitis. Hepatology. 2010;51:2193-2213.全文  摘要

2. Zachou K, Rigopoulou E, Dalekos GN. Autoantibodies and autoantigens in autoimmune hepatitis: important tools in clinical practice and to study pathogenesis of the disease. J Autoimmune Dis. 2004 Oct 15;1(1):2.全文  摘要

3. Krawitt EL. Autoimmune hepatitis. N Engl J Med. 2006 Jan 5;354(1):54-66. 摘要

4. Boberg KM. Prevalence and epidemiology of autoimmune hepatitis. Clin Liver Dis. 2002 Aug;6(3):635-47. 摘要

5. Czaja AJ. Autoimmune hepatitis: approach to diagnosis. MedGenMed. 2006 May 23;8(2):55.全文  摘要

6. Ngu JH, Bechly K, Chapman BA, et al. Population-based epidemiology study of autoimmune hepatitis: a disease of older women? J Gastroenterol Hepatol. 2010 Oct;25(10):1681-6. 摘要

7. Grønbæk L, Vilstrup H, Jepsen P. Autoimmune hepatitis in Denmark: incidence, prevalence, prognosis, and causes of death. A nationwide registry-based cohort study. J Hepatol. 2014 Mar;60(3):612-7. 摘要

8. van Gerven NM, Verwer BJ, Witte BI, et al. Epidemiology and clinical characteristics of autoimmune hepatitis in the Netherlands. Scand J Gastroenterol. 2014 Oct;49(10):1245-54. 摘要

9. Radhakrishnan KR, Alkhouri N, Worley S, et al. Autoimmune hepatitis in children--impact of cirrhosis at presentation on natural history and long-term outcome. Dig Liver Dis. 2010 Oct;42(10):724-8. 摘要

10. Deneau M, Jensen MK, Holmen J, et al. Primary sclerosing cholangitis, autoimmune hepatitis, and overlap in Utah children: epidemiology and natural history. Hepatology. 2013 Oct;58(4):1392-400.全文  摘要

11. Jiménez-Rivera C, Ling SC, Ahmed N, et al. Incidence and characteristics of autoimmune hepatitis. Pediatrics. 2015 Nov;136(5):e1237-48. 摘要

12. Moy L, Levine J. Autoimmune hepatitis: a classic autoimmune liver disease. Curr Probl Pediatr Adolesc Health Care. 2014 Dec;44(11):341-6. 摘要

13. Czaja AJ. Autoimmune liver disease. Curr Opin Gastroenterol. 2006 May;22(3):234-40. 摘要

14. Jenkins A, Austin A, Hughes K, et al. Infliximab-induced autoimmune hepatitis. BMJ Case Rep. 2021 May 24;14(5):e239944. 摘要

15. Franco DL, Kale S, Lam-Himlin DM, et al. Black cohosh hepatotoxicity with autoimmune hepatitis presentation. Case Rep Gastroenterol. 2017 Jan-Apr;11(1):23-8.全文  摘要

16. Manns MP, Vogel A. Autoimmune hepatitis, from mechanisms to therapy. Hepatology. 2006 Feb;43(2 Suppl 1):S132-44. 摘要

17. Doherty DG, Donaldson PT, Underhill JA, et al. Allelic sequence variation in the HLA class II genes and proteins in patients with autoimmune hepatitis. Hepatology. 1994 Mar;19(3):609-15.全文  摘要

18. Wang Q, Yang F, Miao Q, et al. The clinical phenotypes of autoimmune hepatitis: a comprehensive review. J Autoimmun. 2016 Jan;66:98-107. 摘要

19. Potts JR, Verma S. Optimizing management in autoimmune hepatitis with liver failure at initial presentation. World J Gastroenterol. 2011 Apr 28;17(16):2070-5.全文  摘要

20. Braga AC, Vasconcelos C, Braga J. Pregnancy with autoimmune hepatitis. Gastroenterol Hepatol Bed Bench. 2016 Summer;9(3):220-4.全文  摘要

21. Al-Chalabi T, Underhill JA, Portmann BC, et al. Effects of serum aspartate aminotransferase levels in patients with autoimmune hepatitis influence disease course and outcome. Clin Gastroenterol Hepatol. 2008 Dec;6(12):1389-95.全文  摘要

22. Giannini EG, Testa R, Savarino V. Liver enzyme alteration: a guide for clinicians. CMAJ. 2005 Feb 1;172(3):367-79.全文  摘要

23. Zeman MV, Hirschfield GM. Autoantibodies and liver disease: uses and abuses. Can J Gastroenterol. 2010 Apr;24(4):225-31.全文  摘要

24. Manns MP. Antibodies to soluble liver antigen: specific marker of autoimmune hepatitis. J Hepatol. 2000 Aug;33(2):326-8.全文  摘要

25. Sebode M, Weiler-Normann C, Liwinski T, et al. Autoantibodies in autoimmune liver disease-clinical and diagnostic relevance. Front Immunol. 2018 Mar 27;9:609.全文  摘要

26. Martini E, Abuaf N, Cavalli F, et al. Antibody to liver cytosol (anti-LC1) in patients with autoimmune chronic active hepatitis type 2. Hepatology. 1988 Nov-Dec;8(6):1662-6.全文  摘要

27. Abuaf N, Johanet C, Chretien P, et al. Characterization of the liver cytosol antigen type 1 reacting with autoantibodies in chronic active hepatitis. Hepatology. 1992 Oct;16(4):892-8.全文  摘要

28. European Association for the Study of the Liver. EASL clinical practice guidelines: autoimmune hepatitis. J Hepatol. 2015 Oct;63(4):971-1004. 摘要

29. Czaja AJ. Autoimmune liver disease. Curr Opin Gastroenterol. 2005 May;21(3):293-9. 摘要

30. Czaja AJ. Natural history, clinical features, and treatment of autoimmune hepatitis. Semin Liver Dis. 1984 Feb;4(1):1-12. 摘要

31. Sue MJ, Lee EW, Saab S, et al. Transjugular liver biopsy: safe even in patients with severe coagulopathies and multiple biopsies. Clin Transl Gastroenterol. 2019 Jul;10(7):e00063.全文  摘要

32. Maharaj B, Bhoora IG. Complications associated with percutaneous needle biopsy of the liver when one, two or three specimens are taken. Postgrad Med J. 1992 Dec;68(806):964-7.全文  摘要

33. Tonolini M, Bianco R. HIV-related/AIDS cholangiopathy: pictorial review with emphasis on MRCP findings and differential diagnosis. Clin Imaging. 2013 Mar-Apr;37(2):219-26. 摘要

34. Alvarez F, Berg PA, Bianchi FB, et al. International Autoimmune Hepatitis Group Report: review of criteria for diagnosis of autoimmune hepatitis. J Hepatol. 1999 Nov;31(5):929-38. 摘要

35. Hennes EM, Zeniya M, Czaja AJ, et al. Simplified criteria for the diagnosis of autoimmune hepatitis. Hepatology. 2008 Jul;48(1):169-76.全文  摘要

36. Gleeson D, Heneghan MA; British Society of Gastroenterology. British Society of Gastroenterology (BSG) guidelines for management of autoimmune hepatitis. Gut. 2011 Dec;60(12):1611-29.全文  摘要

37. Lamers MM, van Oijen MG, Pronk M, et al. Treatment options for autoimmune hepatitis: a systematic review of randomized controlled trials. J Hepatol. 2010 Jul;53(1):191-8.全文  摘要

38. Yeoman AD, Longhi MS, Heneghan MA. Review article: the modern management of autoimmune hepatitis. Aliment Pharmacol Ther. 2010 Apr;31(8):771-87.全文  摘要

39. Zandieh I, Krygier D, Wong V, et al. The use of budesonide in the treatment of autoimmune hepatitis in Canada. Can J Gastroenterol. 2008 Apr;22(4):388-92.全文  摘要

40. Wiegand J, Schüler A, Kanzler S, et al. Budesonide in previously untreated autoimmune hepatitis. Liver Int. 2005 Oct;25(5):927-34. 摘要

41. Strassburg CP, Manns MP. Treatment of autoimmune hepatitis. Semin Liver Dis. 2009 Aug;29(3):273-85. 摘要

42. Manns MP, Woynarowski M, Kreisel W, et al. Budesonide induces remission more effectively than prednisone in a controlled trial of patients with autoimmune hepatitis. Gastroenterology. 2010 Oct;139(4):1198-206. 摘要

43. Danielsson A, Prytz H. Oral budesonide for treatment of autoimmune chronic active hepatitis. Aliment Pharmacol Ther. 1994 Dec;8(6):585-90. 摘要

44. Czaja AJ, Lindor KD. Failure of budesonide in a pilot study of treatment-dependent autoimmune hepatitis. Gastroenterology. 2000 Nov;119(5):1312-6. 摘要

45. Csepregi A, Röcken C, Treiber G, et al. Budesonide induces complete remission in autoimmune hepatitis. World J Gastroenterol. 2006 Mar 7;12(9):1362-6. 摘要

46. Woynarowski M, Nemeth A, Baruch Y, et al; European Autoimmune Hepatitis-Budesonide Study Group. Budesonide versus prednisone with azathioprine for the treatment of autoimmune hepatitis in children and adolescents. J Pediatr. 2013 Nov;163(5):1347-53.e1. 摘要

47. Yu ZJ, Zhang LL, Huang TT, et al. Comparison of mycophenolate mofetil with standard treatment for autoimmune hepatitis: a meta-analysis. Eur J Gastroenterol Hepatol. 2019 Jul;31(7):873-7. 摘要

48. Selvarajah V, Montano-Loza AJ, Czaja AJ. Systematic review: managing suboptimal treatment responses in autoimmune hepatitis with conventional and nonstandard drugs. Aliment Pharmacol Ther. 2012 Oct;36(8):691-707.全文  摘要

49. Nasseri-Moghaddam S, Nikfam S, Karimian S, et al. Cyclosporine-A versus prednisolone for induction of remission in auto-immune hepatitis: interim analysis report of a randomized controlled trial. Middle East J Dig Dis. 2013 Oct;5(4):193-200.全文  摘要

50. Malekzadeh R, Nasseri-Moghaddam S, Kaviani MJ, et al. Cyclosporin A is a promising alternative to corticosteroids in autoimmune hepatitis. Dig Dis Sci. 2001 Jun;46(6):1321-7. 摘要

51. Molmenti EP, Netto GJ, Murray NG, et al. Incidence and recurrence of autoimmune/alloimmune hepatitis in liver transplant recipients. Liver Transpl. 2002 Jun;8(6):519-26.全文  摘要

52. Chatrath H, Allen L, Boyer TD. Use of sirolimus in the treatment of refractory autoimmune hepatitis. Am J Med. 2014 Nov;127(11):1128-31. 摘要

53. D'Agostino D, Costaguta A, Álvarez F. Successful treatment of refractory autoimmune hepatitis with rituximab. Pediatrics. 2013 Aug;132(2):e526-30. 摘要

54. Weiler-Normann C, Schramm C, Quaas A, et al. Infliximab as a rescue treatment in difficult-to-treat autoimmune hepatitis. J Hepatol. 2013 Mar;58(3):529-34. 摘要

55. Wong F, Al Ibrahim B, Walsh J, et al. Infliximab-induced autoimmune hepatitis requiring liver transplantation. Clin Case Rep. 2019 Sep 27;7(11):2135-9.全文  摘要

56. Karanfilian B, Mahpour N, Sarkar A. Infliximab drug-induced autoimmune hepatitis in a patient with Crohn's ileocolitis. Am J Ther. 2020 Dec 29 [Epub ahead of print]. 摘要

57. Czaja AJ, Carpenter HA, Lindor KD. Ursodeoxycholic acid as adjunctive therapy for problematic type 1 autoimmune hepatitis: a randomized placebo-controlled treatment trial. Hepatology. 1999 Dec;30(6):1381-6. 摘要

58. Joshi S, Cauch-Dudek K, Wanless IR, et al. Primary biliary cirrhosis with additional features of autoimmune hepatitis: response to therapy with ursodeoxycholic acid. Hepatology. 2002 Feb;35(2):409-13.全文  摘要

59. Squires RH, Ng V, Romero R, et al. Evaluation of the pediatric patient for liver transplantation: 2014 practice guideline by the American Association for the Study of Liver Diseases, American Society of Transplantation and the North American Society for Pediatric Gastroenterology, Hepatology, and Nutrition. Hepatology. 2014 Jul;60(1):362-98.全文  摘要

60. Kirk AP, Jain S, Pocock S, et al. Late results of the Royal Free Hospital prospective controlled trial of prednisolone therapy in hepatitis B surface antigen negative chronic active hepatitis. Gut. 1980 Jan;21(1):78-83.全文  摘要

61. Hoeroldt B, McFarlane E, Dube A, et al. Long-term outcomes of patients with autoimmune hepatitis managed at a nontransplant center. Gastroenterology. 2011 Jun;140(7):1980-9.全文  摘要

62. Czaja AJ. Rapidity of treatment response and outcome in type 1 autoimmune hepatitis. J Hepatol. 2009 Jul;51(1):161-7. 摘要

63. Czaja AJ, Menon KV, Carpenter HA. Sustained remission after corticosteroid therapy for type 1 autoimmune hepatitis: a retrospective analysis. Hepatology. 2002 Apr;35(4):890-7.全文  摘要

64. Roberts SK, Therneau TM, Czaja AJ. Prognosis of histological cirrhosis in type 1 autoimmune hepatitis. Gastroenterology. 1996 Mar;110(3):848-57. 摘要

65. Sucher E, Sucher R, Gradistanac T, et al. Autoimmune hepatitis-immunologically triggered liver pathogenesis-diagnostic and therapeutic strategies. J Immunol Res. 2019 Nov 25;2019:9437043.全文  摘要

66. Andries S, Casamayou L, Sempoux C, et al. Posttransplant immune hepatitis in pediatric liver transplant recipients: incidence and maintenance therapy with azathioprine. Transplantation. 2001 Jul 27;72(2):267-72. 摘要

67. Czaja AJ. Special clinical challenges in autoimmune hepatitis: the elderly, males, pregnancy, mild disease, fulminant onset, and nonwhite patients. Semin Liver Dis. 2009 Aug;29(3):315-30. 摘要

68. Czaja AJ, Carpenter HA. Distinctive clinical phenotype and treatment outcome of type 1 autoimmune hepatitis in the elderly. Hepatology. 2006 Mar;43(3):532-8.全文  摘要

69. Miyake T, Miyaoka H, Abe M, et al. Clinical characteristics of autoimmune hepatitis in older aged patients. Hepatol Res. 2006 Oct;36(2):139-42. 摘要

70. Cross TJ, Antoniades CG, Muiesan P, et al. Liver transplantation in patients over 60 and 65 years: an evaluation of long-term outcomes and survival. Liver Transpl. 2007 Oct;13(10):1382-8.全文  摘要

71. Candia L, Marquez J, Espinoza LR. Autoimmune hepatitis and pregnancy: a rheumatologist's dilemma. Semin Arthritis Rheum. 2005 Aug;35(1):49-56. 摘要

72. Francella A, Dyan A, Bodian C, et al. The safety of 6-mercaptopurine for childbearing patients with inflammatory bowel disease: a retrospective cohort study. Gastroenterology. 2003 Jan;124(1):9-17.全文  摘要

73. Natekar A, Pupco A, Bozzo P, et al. Safety of azathioprine use during pregnancy. Can Fam Physician. 2011 Dec;57(12):1401-2.全文  摘要

74. Akbari M, Shah S, Velayos FS, et al. Systematic review and meta-analysis on the effects of thiopurines on birth outcomes from female and male patients with inflammatory bowel disease. Inflamm Bowel Dis. 2013 Jan;19(1):15-22. 摘要

75. Viruet EJ, Torres EA. Steroid therapy in fulminant hepatic failure secondary to autoimmune hepatitis. P R Health Sci J. 1998 Sep;17(3):297-300. 摘要

76. Czaja AJ, Rakela J, Ludwig J. Features reflective of early prognosis in corticosteroid-treated severe autoimmune chronic active hepatitis. Gastroenterology. 1988 Aug;95(2):448-53. 摘要

77. Montano-Loza AJ, Carpenter HA, Czaja AJ. Features associated with treatment failure in type 1 autoimmune hepatitis and predictive value of the model of end-stage liver disease. Hepatology. 2007 Oct;46(4):1138-45. 摘要